ATI RN
ATI Pharmacology
1. A client with increased intracranial pressure is receiving Mannitol. Which finding should the nurse report to the provider?
- A. Blood glucose 150 mg/dL
- B. Urine output 40 mL/hr
- C. Dyspnea
- D. Bilateral equal pupil size
Correct answer: C
Rationale: The correct answer is C: Dyspnea. Dyspnea is a concerning finding in a client receiving Mannitol as it can be a manifestation of heart failure, which is an adverse effect of the medication. The nurse should promptly notify the provider, discontinue the Mannitol, and initiate appropriate interventions to address the dyspnea and monitor the client's condition closely. Choice A, Blood glucose of 150 mg/dL, is within normal limits and not directly related to Mannitol administration. Choice B, Urine output of 40 mL/hr, could indicate decreased renal perfusion, but it is not the most critical finding compared to dyspnea. Choice D, Bilateral equal pupil size, is a normal neurological finding and not directly related to Mannitol therapy.
2. A client has a new prescription for Methotrexate. Which of the following instructions should be included in the teaching?
- A. Avoid drinking alcohol while taking this medication.
- B. Take the medication with a high-fat meal.
- C. Expect increased hair growth.
- D. You should never stop taking the medication without consulting your healthcare provider.
Correct answer: A
Rationale: The correct instruction for a client taking Methotrexate is to avoid drinking alcohol. Methotrexate can cause liver toxicity, and alcohol consumption can increase this risk. It is important to emphasize the avoidance of alcohol while on this medication to prevent adverse effects and ensure treatment effectiveness. The other options are incorrect: Taking Methotrexate with a high-fat meal is not necessary as it can be taken with or without food. Increased hair growth is not an expected effect of Methotrexate; in fact, hair loss is a potential side effect. Stopping the medication without consulting a healthcare provider can be dangerous and may lead to worsening of symptoms or relapse, making option D incorrect.
3. A healthcare professional is preparing to administer a dose of Hydromorphone IV to a client. Which of the following actions should the healthcare professional take?
- A. Administer the medication over 5 minutes.
- B. Administer a dose of Naloxone prior to giving the Hydromorphone.
- C. Assess the client's blood pressure prior to administration.
- D. Inject the medication into the client's subcutaneous tissue.
Correct answer: A
Rationale: The healthcare professional should administer IV Hydromorphone slowly over 5 minutes to reduce the risk of hypotension and respiratory depression. Rapid administration can lead to adverse effects due to its potency. Choice B is incorrect because Naloxone is used as an antidote for opioid overdose, not routinely administered with Hydromorphone. Choice C is important but not specific to the administration of Hydromorphone. Choice D is incorrect as Hydromorphone is intended for intravenous use, not subcutaneous injection.
4. A client has a new prescription for Nitrofurantoin. Which of the following instructions should be included?
- A. Take this medication with food.
- B. Avoid dairy products while taking this medication.
- C. Take this medication at bedtime.
- D. Increase your intake of vitamin C.
Correct answer: A
Rationale: Nitrofurantoin should be taken with food to enhance absorption and reduce gastrointestinal side effects. Taking it with a meal or a snack can help minimize stomach upset. Instructing the client to take the medication with food ensures optimal effectiveness and tolerability of the drug. Choice B is incorrect because there is no specific interaction between Nitrofurantoin and dairy products. Choice C is incorrect as there is no requirement to take Nitrofurantoin at bedtime. Choice D is also incorrect as increasing vitamin C intake is not necessary or relevant to taking Nitrofurantoin.
5. A client has a new prescription for Adalimumab for Rheumatoid Arthritis. Based on the route of administration of Adalimumab, which of the following should the nurse plan to monitor?
- A. The vein for thrombophlebitis during IV administration.
- B. The subcutaneous site for redness following injection.
- C. The oral mucosa for ulceration after oral administration.
- D. The skin for irritation following removal of transdermal patch.
Correct answer: B
Rationale: Adalimumab is administered subcutaneously for Rheumatoid Arthritis. Injection-site reactions such as redness and swelling are common. Therefore, the nurse should monitor the subcutaneous site for redness following the injection to assess for potential adverse effects.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access